These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36314881)

  • 1. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
    Jones GM
    J Psychopharmacol; 2023 Jan; 37(1):61-69. PubMed ID: 36314881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
    Jones G; Arias D; Nock M
    Sci Rep; 2022 Dec; 12(1):21927. PubMed ID: 36535992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.
    Jones G; Lipson J; Wang E
    Sci Rep; 2023 Feb; 13(1):2466. PubMed ID: 36774449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension.
    Jones GM; Ricard JA; Nock MK
    Front Psychiatry; 2024; 15():1169686. PubMed ID: 38979507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests.
    Jones G; Al-Suwaidi M; Castro-Ramirez F; McGuire TC; Mair P; Nock MK
    Front Psychiatry; 2023; 14():1169692. PubMed ID: 37692301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample.
    Jones G; Ricard JA; Hendricks P; Simonsson O
    J Psychopharmacol; 2022 Oct; 36(10):1129-1135. PubMed ID: 36189781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.
    Fonseka LN; Woo BK
    World J Psychiatry; 2023 May; 13(5):182-190. PubMed ID: 37303932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Correlates of Past Year Ecstasy/MDMA Use in the United States.
    Yang KH; Kepner W; Nijum A; Han BH; Palamar JJ
    J Addict Med; 2023 Sep-Oct 01; 17(5):592-597. PubMed ID: 37788615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):66-73. PubMed ID: 35090364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.